Also trades as: TVGNW (NASDAQ) · $vol 0M
TVGN NASDAQ
Tevogen Bio Holdings Inc.
1W: +24.5%
1M: +44.1%
3M: -16.4%
YTD: +3124.3%
1Y: +911.2%
3Y: +4.7%
$9.61
-1.90 (-16.51%)
Weekly Expected Move ±25.1%
$4
$6
$8
$11
$13
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$40.2M
52W Range4.135-75.5
Volume46,931
Avg Volume33,534
Beta0.10
Dividend—
Analyst Ratings
Company Info
CEORyan H. Saadi
Employees18
SectorHealthcare
IndustryBiotechnology
IPO Date2022-01-05
Websitetevogen.com
15 Independence Blvd
Warren, NJ 07059
US
Warren, NJ 07059
US
877 838 6436
About Tevogen Bio Holdings Inc.
Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey.
Latest News
Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services Organization
Tevogen Bio Holdings reports Q1 results; operating loss falls 48%
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Flomenberg Neal | S-Sale | 501 | $6.40 | 2026-03-13 |
| Flomenberg Neal | S-Sale | 452 | $7.26 | 2026-03-11 |
| Flomenberg Neal | S-Sale | 19 | $7.75 | 2026-03-10 |
| Saadi Ryan H. | G-Gift | 50,000 | — | 2025-12-18 |
| Desai Kirti | G-Gift | 300,000 | — | 2025-12-11 |